What question did this study set out to answer?

To report initial mortality and survival findings from a randomized trial comparing iodine 125 brachytherapy with enucleation in patients with choroidal melanoma.

July 1, 2001Archives of Ophthalmology

The COMS Randomized Trial of Iodine 125 Brachytherapy for Choroidal Melanoma, III: Initial Mortality Findings

View Full Paper

Ask AI

Bookmark

Authors

MDMarie Diener‐WestJohns Hopkins University JEJohn D. EarleMayo Clinic SFShai FineReichman University

Discussion

Member takes

Implication

Randomized trial reports equivalent survival with iodine 125 brachytherapy versus enucleation in choroidal melanoma, indicating eye-preserving radiation does not compromise mortality.

Key Points

To report initial mortality and survival findings from a randomized trial comparing iodine 125 brachytherapy with enucleation in patients with choroidal melanoma.
Multicenter randomized clinical trial across 43 centers in the United States and Canada enrolling 1,317 patients assigned to enucleation (n=660) or iodine 125 brachytherapy (n=657).
Patients were monitored over an 11.5-year accrual period, with 81% evaluated for mortality at 5 years and 32% followed for 10 years, analyzed by intention to treat.
Overall mortality occurred in 188 of 660 patients (28%) in the enucleation arm and 176 of 657 patients (27%) in the brachytherapy arm, yielding 5-year survival rates of 81% versus 82% (P = .48; adjusted RR 0.99, 95% CI, 0.80–1.22).
Five-year rates of death with confirmed melanoma metastasis were 11% following enucleation and 9% following brachytherapy (adjusted RR 0.91, 95% CI, 0.66–1.24).

Cite This Study

Diener‐West et al. (2001) studied this question.

synapsesocial.com/papers/6a7ba76711f9f91080ed1f1f https://doi.org/10.1001/archopht.119.7.969

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial reports equivalent survival with iodine 125 brachytherapy versus enucleation in choroidal melanoma, indicating eye-preserving radiation does not compromise mortality.

The COMS Randomized Trial of Iodine 125 Brachytherapy for Choroidal Melanoma, III: Initial Mortality Findings

Discussion

Member takes

Implication

Key Points

Cite This Study

The COMS Randomized Trial of Iodine 125 Brachytherapy for Choroidal Melanoma, III: Initial Mortality Findings

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider